Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18535491 | 0.89 | USP2 (0.40) | NPSR1USP2TSHRCYP1A2 | |
| SCHEMBL12946062 | 0.89 | USP2 (0.40) | NPSR1USP2TSHRCYP1A2 | |
| SCHEMBL19199025 | 0.89 | TSHR (0.36) | USP2TSHRCYP1A2 | |
| SCHEMBL26041077 | 0.88 | TSHR (0.38) | NPSR1USP2TSHRCYP1A2 | |
| SCHEMBL1375292 | 0.88 | TSHR (0.38) | NPSR1USP2TSHRCYP1A2 | |
| SCHEMBL27380027 | 0.88 | TSHR (0.38) | NPSR1USP2TSHRCYP1A2 | |
| SCHEMBL20411533 | 0.88 | TSHR (0.38) | NPSR1USP2TSHRCYP1A2 | |
| SCHEMBL13890773 | 0.88 | TSHR (0.38) | NPSR1USP2TSHRCYP1A2 | |
| SCHEMBL20047143 | 0.88 | TSHR (0.38) | NPSR1USP2TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL1373582 | 0.86 | TSHR (0.37) | NPSR1USP2TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | PDPK1, PIK3CA, PI4KA | NPSR1 3892/4885USP2 3125/4885KMT2A 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.